New Breast Cancer Drug Approved by FDA -- HER-2 Positive Late Stage Breast Cancer
Kadcyla delivers the drug to the cancer site to shrink the tumor, slow disease progression and prolong survival. It is the fourth approved drug that targets the HER2 protein.
In a randomized trial of nearly 1000 patients, progression-free survival was longer with T-DM1 than with lapatinib plus capecitabine (9.6 vs. 6.4 months). The approval has been "eagerly anticipated," says Journal Watch Oncology and Hematology Editor-in-Chief Dr. William Gradishar. He says he expects that the drug will become "the preferred treatment" in eligible patients.
Get the FDA Press Release: